Results 111 to 120 of about 20,538 (302)

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs

Neuropsychiatric Disease and Treatment, 2023
Nbaa Masood, Joohi Jimenez-Shahed Department of Neurology, Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, NY, USACorrespondence: Joohi Jimenez-Shahed, Associate Professor of Neurology & Neurosurgery, Icahn School of Medicine at ...
Masood N, Jimenez-Shahed J
doaj  

Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

Neurobiology of Disease, 2004
Alterations of striatal glutamate receptors are believed to be responsible, at least in part, for the pathogenesis of l-dopa-induced dyskinesias (LID). To evaluate whether co-administration of CI-1041, a novel NMDA receptor antagonist selective for the ...
Abdallah Hadj Tahar, Laurent Grégoire, Aurélie Darré, Nancy Bélanger, Leonard Meltzer, Paul J Bédard   +5 more
doaj   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source

Acute hemichorea‐hemiballism as the initial sign of cortical cerebral infarction: A case report

Neuroprotection
Hemichorea‐hemiballism is classically associated with the contralateral basal ganglia, particularly involving the putamen and subthalamic nucleus, whereas cortical involvement remains a rare etiology.
Jin Xiong, Qian Yang, Yong Liu, Jianping Yu, Yili Wang, Lan Wen   +5 more
doaj   +1 more source

The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician [PDF]

, 2013
A growing number of progressive heredodegenerative conditions mimic the presentation of Huntington's disease (HD). Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline ...
Bhatia, KP, Martino, D, Stamelou, M
core  

Severity‐Based and Family‐Centered Approaches to Deep Brain Stimulation in GNAO1‐Related Disorders

Movement Disorders Clinical Practice, EarlyView.
Jana Domínguez‐Carral, Juan Darío Ortigoza‐Escobar   +1 more
wiley   +1 more source

Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson’s disease [PDF]

, 2011
Behavioural abnormalities such as impulse control disorders may develop when patients with Parkinson’s disease receive dopaminergic therapy, although they can be controlled by deep brain stimulation of the subthalamic nucleus.
Alegre-Esteban, M. (Manuel), Artieda, J. (Julio), Garcia-Garcia, D. (David), Guridi-Legarra, J. (Jorge), Lopez-Azcarate, J. (Jon), Obeso, J.A. (José A.), Rodriguez-Oroz, M.C. (María Cruz), Toledo, J. (Jon)   +7 more
core